Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human T-lymphotropic virus 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    211 result(s) found for: Human T-lymphotropic virus 2. Displaying page 7 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2014-000828-24 Sponsor Protocol Number: ANRS163ETRAL Start Date*: 2015-05-31
    Sponsor Name:Inserm-ANRS
    Full Title: A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with a...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002499-16 Sponsor Protocol Number: TMC125-C214 Start Date*: 2006-12-22
    Sponsor Name:Janssen R&D Ireland
    Full Title: Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004454-30 Sponsor Protocol Number: DORA-HD Start Date*: 2021-01-27
    Sponsor Name:Fundació FLS de Lluita contra la SIDA, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Removal of Doravirine by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
    Medical condition: Patients with HIV and end stage renal disease (ESRD) undergoing on intermittent hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10014646 End stage renal disease (ESRD) LLT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016226-13 Sponsor Protocol Number: ANRS 151 Start Date*: 2009-10-15
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales
    Full Title: Etude de phase II randomisée évaluant l'immunogénicité et la tolérance du vaccin antigrippal A(H1N1)v adjuvanté comparativement au vaccin antigrippal A(H1N1)v non adjuvanté chez des patients infect...
    Medical condition: infection VIH et vaccination anti-grippe A (H1N1)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10016794 Flu vaccination LLT
    12.0 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014616-36 Sponsor Protocol Number: ANRS148 Start Date*: 2009-11-19
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS.
    Full Title: Etude pilote de la pharmacocinétique, de la tolérance et de l’efficacité du raltégravir associé à deux molécules actives parmi les analogues nucléosi(ti)diques et l’enfuvirtide, avant et après tran...
    Medical condition: Période 1 : Hepatic insufficiency Période 2 Liver transplantation chez les patients infectés par le VIH-1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10056542 LLT
    12.0 10024716 LLT
    12.0 10020161 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005238-23 Sponsor Protocol Number: MCA-896 Start Date*: 2016-10-18
    Sponsor Name:Rockefeller University
    Full Title: A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001287-23 Sponsor Protocol Number: TMC125-C217 Start Date*: 2006-06-13
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216).
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003052-31 Sponsor Protocol Number: TMC114IFD3013 Start Date*: 2015-02-17
    Sponsor Name:Janssen R&D, Ireland
    Full Title: A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004379-20 Sponsor Protocol Number: A5271015 Start Date*: 2008-12-11
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITA...
    Medical condition: HIV in particular against drug-resistant virus, especially the clinically significant mutants (K103N, Y181C, and L100I)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000437-36 Sponsor Protocol Number: AI438011/205889 Start Date*: 2012-08-14
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open...
    Medical condition: Human immunodeficiency virus type 1 (HIV-1)-infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005823-34 Sponsor Protocol Number: ING117172 Start Date*: 2013-10-11
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in...
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) ES (Completed) PT (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004435-31 Sponsor Protocol Number: MVC116278 Start Date*: 2012-05-15
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004306-50 Sponsor Protocol Number: A4001050 Start Date*: 2007-04-23
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002632-14 Sponsor Protocol Number: ODYSSEY(PENTA20) Start Date*: 2016-03-21
    Sponsor Name:Fondazione PENTA ONLUS
    Full Title: A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART
    Medical condition: Paediatric HIV infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) PT (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-001430-32 Sponsor Protocol Number: M05-730 Start Date*: 2005-11-18
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N...
    Medical condition: HIV-1 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003133-16 Sponsor Protocol Number: P04875 Start Date*: 2008-02-15
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects
    Medical condition: HIV INFECTION IN NAIVE PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000748-14 Sponsor Protocol Number: M06-802 Start Date*: 2006-08-14
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib...
    Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available.
    Disease: Version SOC Term Classification Code Term Level
    9.0 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022775-57 Sponsor Protocol Number: JF002 Start Date*: 2011-06-09
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: Effects of Vitamin D supplementation on Vitamin D levels and immune activation in HIV infected individuals on antiretroviral therapy-A pilot study.
    Medical condition: HIV infected patients with vitamin D defficiency
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10020189 HIV test positve LLT
    14.1 10022891 - Investigations 10020180 HIV positive LLT
    14.1 10021881 - Infections and infestations 10020160 HIV disease LLT
    14.1 10022891 - Investigations 10020181 HIV positve LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022120-72 Sponsor Protocol Number: JF-001 Start Date*: 2010-12-17
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs).
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    14.1 10022891 - Investigations 10020180 HIV positive LLT
    14.1 10022891 - Investigations 10020188 HIV test positive PT
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001518-27 Sponsor Protocol Number: MK-1439-027 Start Date*: 2018-02-27
    Sponsor Name:NIAID, NICHD, NIMH
    Full Title: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescen...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:05:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA